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ABSTRACT Genome sequence analysis reveals that
all organisms synthesize S-adenosylmethionine (AdoMet)
and that a large fraction of all genes is AdoMet-
dependent methyltransferases. AdoMet-dependent
methylation has been shown to be central to many
biological processes. Up to 85% of all methylation
reactions and as much as 48% of methionine metabo-
lism occur in the liver, which indicates the crucial
importance of this organ in the regulation of blood
methionine. Of the two mammalian genes (MAT1A,
MAT2A) that encode methionine adenosyltransferase
(MAT, the enzyme that makes AdoMet), MAT1A is
specifically expressed in adult liver. It now appears that
growth factors, cytokines, and hormones regulate liver
MAT mRNA levels and enzyme activity and that
AdoMet should not be viewed only as an intermediate
metabolite in methionine catabolism, but also as an
intracellular control switch that regulates essential he-
patic functions such as regeneration, differentiation,
and the sensitivity of this organ to injury. The aim of
this review is to integrate these recent findings linking
AdoMet with liver growth, differentiation, and injury
into a comprehensive model. With the availability of
AdoMet as a nutritional supplement and evidence of its
beneficial role in various liver diseases, this review
offers insight into its mechanism of action.—Mato,
J. M., Corrales, F. J., Lu, S. C., Avila, M. A. S-Adeno-
sylmethionine: a control switch that regulates liver
function. FASEB J. 16, 15–26 (2002)
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The identification by Cantoni in 1951 of S-adenosyl-
methionine (AdoMet, also abbreviated SAM) was based
on the earlier demonstration by du Vigneaud of the
transfer of the methyl group of methionine to creatine
(1). In 1958, Tabor’s group demonstrated that after
decarboxylation, AdoMet could donate the pro-
pylamino moiety attached to the sulfonium ion to
putrescine to form spermidine and methylthioad-
enosine and to spermidine in order to form spermine
and a second molecule of methylthioadenosine (2). Du
Vigneaud and others demonstrated in the late 1930s
that methionine is a metabolic precursor of homocys-
teine and, in the late 1950s, the methylation of homo-
cysteine to form methionine, an integrated view com-
bining the transmethylation and transsulfuration
pathways was finally provided by Laster’s group in 1964
(Fig. 1) (3). This seminal work of du Vigneaud, Can-
toni, and others provided a perspective of methionine
metabolism where AdoMet could be viewed as the main
biological methyl donor. Since then, AdoMet-depen-
dent methylation has been shown to be central to many
biological processes from metal detoxification through
biosynthesis to gene regulation via DNA methylation.
Moreover, analysis of genome sequences from archaea,
eubacteria, fungi, plants, and animals reveals that all
organisms synthesize AdoMet and that a surprisingly
large fraction of all genes are AdoMet-dependent meth-
yltransferases.
The crucial importance of the liver in the regulation
of blood methionine concentration was first established
by Kinsell et al. in 1947 (4), who showed a marked
impairment of methionine metabolism in patients with
liver cirrhosis. Later work, mainly by the laboratories of
Finkelstein and Mudd, demonstrated that under nor-
mal conditions, both in humans and rats,  85% of all
methylation reactions and 50% of methionine metab-
olism occur in the liver (5, 6). These authors estimated
that the half-life of AdoMet in the liver is 5 min. In
normal liver, the majority of AdoMet is used in meth-
ylation reactions, since the AdoMet decarboxylation
pathway accounts for less than 10% of the available
AdoMet. In humans, the fraction of available homocys-
teine converted to cystathionine during each cycle is
53% and this percent drops to 20% when the dietary
content of methyl groups is restricted. A central role of
AdoMet in the regulation of hepatic methionine me-
tabolism was first proposed by Finkelstein based on his
findings that AdoMet activated cystathionine -synthase
(CBS) and inactivated betaine-homocysteine methyl-
transferase (7–9), and on the earlier observation of
Kutzbach and Stokstad that AdoMet inhibited methyl-
enetetrahydrofolate reductase (10, 11). Today, when
the discovery of AdoMet reaches its 50 anniversary, this
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molecule is enjoying increased attention and promises
to contribute significantly to our understanding of liver
function. It now appears that growth factors, cytokines,
and hormones regulate hepatic AdoMet synthesis and
that AdoMet should not be viewed only as the principal
biological methyl donor and a regulator of methionine
metabolism, but also as an intracellular signal that
controls essential hepatic functions such as hepatocyte
growth and differentiation as well as sensitivity to liver
injury.
1. BIOSYNTHESIS OF S-ADENOSYLMETHIONINE
AdoMet is synthesized from L-methionine and ATP in a
two-step reaction where the complete tripolyphosphate
(PPPi) moiety is cleaved from ATP as AdoMet is being
formed. This unusual reaction is catalyzed by the
enzyme methionine adenosyltransferase (MAT, EC
2.5.6.1.; also abbreviated SAM synthetase) (12). The
biosynthesis of AdoMet has been studied by the groups
of Mudd (13) and Markham (14) using MAT purified
from Escherichia coli and mammals, respectively. The
cloning and sequencing of the structural genes or
cDNAS encoding for a large variety of MATs, including
Mycoplasma genitalium, E. coli, Saccharomyces cerevisiae,
Arabidopsis thaliana, mouse, rat, and human liver, and
mouse, rat, and human kidney, have revealed that MAT
is an exceptionally well-conserved enzyme through evo-
lution (15). MAT from E. coli and humans share 59%
sequence identity (16).
MAT from E. coli has been crystallized and the
structure solved with a resolution of 2.8 Å (17). The
active enzyme exists as a tetramer of a single subunit of
383 amino acids. Each subunit consists of three struc-
tural domains related to each other by a pseudo
threefold symmetry. Pairs of subunits form dimers, and
each dimer is a tight complex, with a wide interface
area between subunits that accommodates two active
sites. The active site of the enzyme is made by both
subunits. The crystal structure of the tetrameric form of
MAT (MAT I) from rat liver has been solved with a
resolution of 2.7 Å and the geometry of the binding site
of methionine identified (18). Each MAT I subunit
consists of 396 amino acids and, as expected, the
tetramer structure is essentially the same as that of the
E. coli enzyme with all of the polar active site residues
conserved.
Replacement of arginine 264 by histidine (R265H) of
MAT I results in a monomeric MAT with undetectable
AdoMet synthetic activity (19). The tripolyphosphatase
activity of the R265H mutant was similar to that found
in the wild-type MAT. These data suggest that the active
site of MAT has two coordinated subsites: a synthetic
site, configured by amino acid residues from both
subunits (17), that is responsible for the binding of
methionine and ATP and performs the AdoMet syn-
thetic reaction; and a hydrolytic site, configured by
amino acid residues from one single subunit, which
accounts for the binding of PPPi and performs the PPPi
hydrolytic reaction.
In the crystal structure of E. coli MAT crystallized at
26°C, residues 102 to 107, which are located over the
active site, are not visible in the electron density maps
and have been suggested to form a ‘flexible loop’ (17).
When the crystallization temperature was decreased
(4°C), the amino acid residues forming the loop were
in a fixed conformation sealing the active site and
preventing the binding of substrates (20). It has been
proposed that when a substrate/product binds in the
active site, the loop becomes flexible and acts as a
‘mobile flap’ in the catalytic reaction (20). In the crystal
structure of rat liver MAT I, the region comprised by
residues 118 to 128 (located over the active site and
Figure 1. Hepatic methionine metabolism. Methi-
onine (Met) is converted into homocysteine (Hcy)
via S-adenosylmethionine (AdoMet) and S-adeno-
sylhomocysteine (AdoHcy). The conversion of Met
into AdoMet is catalyzed by the enzyme methio-
nine adenosyltransferase (MAT). After decarbox-
ylation, AdoMet can donate the remaining pro-
pylamino moiety attached to its sulfonium ion to
putrescine to form spermidine and methylthioad-
enosine (MTA) and to spermidine to form sperm-
ine and a second molecule of MTA. AdoMet
donates its methyl group in a large variety of
reactions catalyzed by dozens of methyltransferase
(MTs), the most abundant in the liver being
glycine-N-methyltransferase (GNMT). The AdoHcy
thus generated is hydrolyzed to form Hcy and aden-
osine through a reversible reaction catalyzed by the
enzyme AdoHcy hydrolase. The methylation of Hcy
to form methionine is catalyzed by two enzymes:
methionine synthase (MS) and betaine methyltrans-
ferase (BHMT). Hcy, in the presence of serine, forms
cystathionine in a reaction catalyzed by the enzyme
cystathionine -synthetase (CBS). Cystathionine is then hydrolyzed to form cysteine, a precursor of the synthesis of glutathione
(GSH). THF, tetrahydrofolate; 5,10-MTHF, methylenetetrahydrofolate; 5-MTHF, methyltetrahydrofolate; Ser, serine; Gly, glycine; X,
methyl acceptor molecule; X-CH3, methylated molecule.
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corresponding to the flexible loop in E. coli) is disor-
dered. However, in contrast to the results in E. coli, the
conformation of the flexible loop in MAT I was not
temperature dependent, suggesting that the mobility of
this loop might be a consequence of its direct involve-
ment in catalysis (18). Whereas the exact function of
this loop remains unclear, the finding that S-nitrosyla-
tion of cysteine 121 completely inactivates MAT I (21)
clearly indicates that the flexible loop plays an impor-
tant role in enzyme activity. Flexible loops have been
identified in many protein structures and, in several
cases, have been located over the active sites and found
to play important roles in enzyme activity. An align-
ment of 11 MAT sequences in the region of the flexible
loop indicates that this region is relatively poorly con-
served compared with other parts of the sequence and
that the aligned sequences vary in length by two to
three residues in this region (20). It has been suggested
that the differences in kinetic properties of different
MATs may be due in part to differences in the compo-
sition of the flexible loop (20).
2. MAMMALIAN MATS
Three distinct forms of MAT (MAT I, MAT II, and MAT
III) have been identified in mammalian tissues that are
the products of two different genes (MAT1A and
MAT2A) (13). Kinetic and regulatory properties of the
different MAT isoforms in mammalian tissues are sum-
marized in Table 1. The gene MAT2A encodes a 396
amino acid catalytic subunit (2) expressed in all
mammalian tissues that have been examined including
erythrocytes, lymphocytes, brain, kidney and fetal liver,
and to a lesser extent in adult liver (12, 15, 22, 23). The
structural and kinetic properties of MAT II have been
studied by the group of Kotb. MAT II consists of 2 and
 subunits (22).The exact way in which the 2 and 
subunits interact is not yet known. The  subunit is a
noncatalytic 334 amino acid protein that has no se-
quence homology with the 2 subunit, but has a
similarity to enzymes that catalyze the reduction of
dTDP-linked sugars (24). Although this reaction has
been best studied in bacteria (25), a BLAST search
reveals the occurrence of a cDNA from mammalian
cells encoding a protein with high similarity to the
enzymes that catalyze the reduction of dTDP-linked
sugars (26). Whether the  subunit has dTDP reductase
activity is not yet known. The fact that the expression of
the 2 subunit in E. coli yields an active enzyme indi-
cates that the  subunit is not necessary for MAT II
activity (27).The function of the  subunit is to regulate
MAT II activity by lowering its Km for L-methionine and
by increasing the sensitivity of the enzyme to feedback
inhibition by AdoMet (27). Therefore, regulation of
the expression of the  subunit may be a mechanism to
regulate the intracellular content of AdoMet. This has
been shown in T cells where superantigen stimulation
leads to a marked reduction in the expression of the 
subunit and a fivefold increase in the cellular AdoMet
content (28).
The gene MAT1A encodes a 395 amino acid catalytic
subunit (1) that organizes into dimers, MAT III, and
tetramers, MAT I (12, 15). The 1 and 2 subunits
share an amino acid sequence identity of 84% (12).
MAT1A is expressed only in adult liver (23), predomi-
nantly in the parenchymal cells, although liver endo-
thelial and Kupffer cells have been recently reported to
express this gene (29). In developing rat liver, MAT1A
expression increases progressively from day 20 of ges-
tation, increases 10-fold immediately after birth, and
reaches a peak at 10 days of age, decreasing slightly by
adulthood (23). Conversely, MAT2A expression de-
creases toward birth, increases threefold in the new-
born, and decreases further in the postnatal life, reach-
ing a minimum in the adult (23). Consequently, under
normal conditions the contribution of MAT II to the
hepatic metabolism of methionine is probably negligi-
ble due to the small amount of this enzyme expressed
in normal liver compared to MAT I and MAT III. It is
obvious that the developmental pattern of MAT1A and
MAT2A are closely related to those of albumin and
-fetoprotein, respectively, suggesting that MAT1A is a
marker for hepatocyte differentiation (23).
For many years, it has been intriguing why there are
two different MAT isoforms in the liver. The majority of
methionine is metabolized by this organ and therefore
the existence of two different MAT isoforms might be
an adaptation to cope with the special metabolic re-
quirements of the liver. In contrast to other mamma-
lian enzymes, methionine has recently been shown to
switch MAT III, the predominant liver form, to a higher
specific activity conformation, a phenomenon known as
hysteretic behavior (30). This has been demonstrated
both in vitro with the purified enzyme and in vivo in
isolated rat hepatocytes exposed to various physiologi-
TABLE 1. Summary of properties of MAT isoforms in mammalian tissuesa
MAT
isoform Gene
Catalytic
subunit
Regulatory
subunit
Subunit
arrangement
Tissue
localization
Km (Met)
M
Km (ATP)
mM
Regulation by
ROS and NO
Inhibition by
AdoMet
MAT I MAT1A 1 No (1)4 Adult liver 20; 600 0.2  No
MAT III MAT1A 1 No (1)2 Adult liver 120 1  No
MAT II MAT2A 2  (2)xy
Extrahepatic
tissues, fetal
liver, HCC. 80 0.03 No 
a See text for a detailed description of the regulatory and kinetic properties of the different MAT isoforms in mammalian tissues.
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cal concentrations of methionine (30). The kinetic
behavior of MAT I has also been studied by several
laboratories, and different Km values for ATP and
methionine have been reported (12). Highly purified
rat liver MAT I was found to have a sigmoidal kinetics
for methionine that could be divided into two com-
ponents: one with a Km of 600 M and the second
with a Km of 20 M (31). The Km for ATP was 200
M (31).
It seems that the availability of methionine is proba-
bly the determining factor that regulates MAT III
activity. The concentration of methionine in rat hepa-
tocytes is between 50 and 80 M (6). Under these
conditions, MAT III will be predominantly in the low
specific activity conformation and the enzyme respon-
sible for AdoMet synthesis will be MAT I. However,
after an increase in methionine concentration, i.e.,
after a protein-rich meal, conversion to the high activity
MAT III form would occur and methionine excess will
be rapidly eliminated. Such a mechanism would be very
sensitive to changes in methionine concentration.
The liver also contains glycine N-methyltransferase
(GNMT), a liver-specific enzyme that accounts for1%
of the cytosolic protein in this organ, shows positive
cooperativity for AdoMet, and whose main function
seems to be to remove excess AdoMet synthesized
during a methionine load (32). In this way, when large
quantities of AdoMet are synthesized by the liver, the
excess of this molecule is not used to hypermethylate
DNA or proteins or for the synthesis of polyamines,
which may be harmful to the liver, but is converted
rapidly into S-adenosylhomocysteine by GNMT (Fig. 1).
Human subjects with GNMT deficiency have an enor-
mous increase in plasma AdoMet and methionine levels
(33). Whereas the increase in plasma AdoMet can easily
be explained by the reduction in GNMT activity, the
relationship between GNMT deficiency and hyperme-
thioninemia is less clear.
3. POST-TRANSLATIONAL REGULATION OF
MAT ACTIVITY
The energy required to catabolize methionine is high.
For each molecule of AdoMet synthesized, the three
high-energy phosphodiester bonds of ATP are hydro-
lyzed. This may be one reason why MAT1A expression
is limited to the liver, an organ with a high capacity to
synthesize ATP. Conditions that impair the hepatic
capacity to maintain normal ATP levels, as during septic
shock or episodes of hypoxia, induce liver MAT inacti-
vation (34, 35). This may be a compensatory mecha-
nism to spare ATP and prevent hepatocytes from
becoming vulnerable to ATP depletion when energy
needs increase acutely. The results showing that expres-
sion of MAT1A in nonhepatic cells, such as CHO cells,
led to a marked reduction of ATP content and higher
sensitivity to cell injury induced by oxidative stress (36)
support this concept.
Nitric oxide (NO) and reactive oxygen substances
(ROS) have been shown to switch MAT I and MAT III
to an inactive conformation through S-nitrosylation
(formation of a SNO group) and oxidation (forma-
tion of a SOH group) of a single cysteine residue in
position 121 (C121), respectively. The 1 subunit from
which MAT I and MAT III are made contains 10
cysteine residues. It has been shown that only replace-
ment of cysteine 121 by serine (C121S) yields an active
enzyme that is resistant to NO and ROS inactivation
(34, 37). Cysteine 121 is located over the active site of
the enzyme in the flexible loop described in section 1
of this review, suggesting that the covalent modification
of this thiol group switches MAT I/III to an inactive
conformation (21). Protein S-nitrosylation involves an
acid base-catalyzed nitrosothiol SNO/SH exchange re-
action where the target cysteine is surrounded by basic
and acidic amino acids that reduce the pKa of its thiol
group and make it more nucleophilic (38). Accord-
ingly, MAT S-nitrosylation has been shown to be regu-
lated by the basic (Arg 357, Arg 363) and acidic (Asp
355) amino acids surrounding the target thiol; replace-
ment of any of these three residues by serine markedly
reduces the capacity of NO to S-nitrosylate and inacti-
vate liver MAT (21). In MAT II, Arg 357, Arg 363, and
Asp 355 are conserved but the equivalent position to
C121 in MAT I/III is occupied by a residue of glycine
(G120). MAT II is not inactivated by NO, but replace-
ment of G120 by cysteine (G12°C) yields an active
enzyme that, in the presence of NO donors, is S-
nitrosylated and inactivated (39). An alignment of a
large variety of MATs cloned from bacteria, yeast,
plants, Drosophila, mouse, rat, and human liver, and
mouse, rat, and human kidney has revealed that the
presence of a cysteine residue in position 121 is char-
acteristic of the liver enzymes and that all other MATs
have a different amino acid in this position, most often
a residue of glycine.
Inactivation of MAT I and MAT III by NO or ROS is
reversed by physiological (millimolar) concentrations
of glutathione (GSH) (34, 37, 40). In isolated rat
hepatocytes, incubation with NO donors or inhibition
of GSH synthesis induces the S-nitrosylation and inac-
tivation of MAT and a reduction in AdoMet content
(41). Removal of the NO donor from the incubation
media or restoration of the cellular GSH levels leads to
the denitrosylation and reactivation of liver MAT and to
the rapid recovery of AdoMet content (41). Intraperi-
toneal (i.p.) injection of bacterial lipopolysaccharide
(LPS) to rats results in S-nitrosylation and inactivation
of hepatic MAT (40). Similarly, inhibition in rats of
GSH synthesis by i.p. injection of buthionine sulfoxi-
mine leads to the S-nitrosylation and inactivation of
hepatic MAT (41).
Liver MAT I/III activity seems to be regulated in a
minute-to-minute basis by NO and ROS (which main-
tain the enzyme in an inactive conformation) and by
GSH (which reactivates the enzyme). This may be the
mechanism by which a variety of conditions that induce
oxidative stress (septic shock, ethanol, hepatitis B- and
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hepatitic C-induced liver cirrhosis, CCl4) or increase
NO synthesis (hypoxia, liver regeneration, cytokines)
inactivate hepatic MAT I/III (15, 34, 35, 42–44). More-
over, these results suggest that liver MAT I/III inactiva-
tion may be a key signal to respond to injury.
4. REGULATION OF MAT1A AND MAT2A
EXPRESSION
MAT1A, MAT2A, and MAT2B promoters have been
cloned and sequenced (45–49). The murine and rat
MAT1A promoters share limited similarities to the
human promoter. The rat and human MAT1A promot-
ers contain several consensus binding sites for C/EBP
(CAAT enhancer binding protein), NF-1 (nuclear fac-
tor 1), and HNF (hepatocyte-enriched nuclear factor),
transcriptional factors important in liver-specific gene
expression (47–49) (Fig. 2). Two regions spanning
nucleotides 1251 to 958 and 197 to 65 were
found to be crucial for promoter efficiency in the rat
promoter (47). Eight protein binding sites have been
characterized in both regions by DNase I footprinting
analysis, and two of these regions were found to be
essential for the regulation of promoter activity. One
region contains a NF1 site, suggesting that NF1, which
usually acts as a positive transcription factor, plays a key
role in directing MAT1A expression. The second re-
gion appears to interact with a member of the HNF-3
family when nuclear extracts from rat liver and H35
hepatoma cells were used, but an additional binding
activity to an HNF-1-like protein was obtained with the
hepatoma cell extracts (47). It has been suggested that
this differential binding may contribute to the negative
regulation of MAT1A in human hepatocellular carci-
noma (HCC; 47). The MAT1A promoter contains sev-
eral GRE (glucocorticoid response element) consensus
binding sites (47). Consistently, glucocorticoid treat-
ment has been shown to increase rat and human
MAT1A expression and promoter activity in a dose- and
time-dependent manner (49, 50).
Functional analysis by transient transfection has
shown that the rat MAT1A promoter is active not only
in hepatocytes and liver-type cells such as the human
hepatoma cell line HepG2, but also in a nonhepatic cell
such as CHO cells (47). These findings suggest that the
liver-restricted expression of the endogenous gene is
not mediated by the action of tissue-specific factors. It
was then found that MAT1A promoter is hypermethyl-
ated at two CpG sites in extrahepatic tissues and fetal
liver but unmethylated in adult liver, where the gene is
actively transcribed (51, 52). It has been demonstrated
that elevated levels of histone acetylation are critical to
maintain a decondensed and active state of the chro-
matin and the underlying pattern of CpG methylation
modulates histone acetylation (53, 54). Accordingly,
the degree of acetylation of histones (H4) associated
with MAT1A promoter in the liver is 15-fold higher
than in the kidney (51, 52). In rat and human-derived
hepatoma cell lines and HCC, MAT1A is expressed at
reduced or undetectable levels whereas MAT2A expres-
sion is markedly induced (55, 56). It has been found
that MAT1A is hypermethylated in HepG2 cells and
that treatment of these cells with the demethylating
agent 5-aza-2-deoxycytidine or the histone deacetylase
inhibitor trichostatin A results in the induction of
MAT1A expression (51). Taken together, these obser-
vations indicate that mechanisms involving DNA meth-
ylation and histone deacetylation may be the main
factors responsible for liver-restricted expression of
MAT1A as well as its silencing in neoplastic transforma-
tion.
Independent of the etiology (alcohol, hepatitis B,
hepatitis C, etc.), MAT1A is expressed at reduced and,
in some cases, undetectable levels in human liver
cirrhosis whereas the expression of MAT2A remains low
(56). It has been shown that MAT1A promoter is
hypermethylated in the liver of cirrhotic patients (56),
suggesting that this and the increased production of
ROS and NO (see section 3 of this review) may be
responsible for the impaired hepatic MAT activity (42,
55), increased serum levels of methionine (56, 57), and
abnormal clearance of this amino acid (4, 42, 57) in
human liver cirrhosis. Understanding why MAT1A be-
Figure 2. Schematic representation
of putative transcription factor bind-
ing sites in human MAT1A and
MAT2A promoters. HNF-3B (hepa-
tocyte-enriched nuclear factor 3B),
GRE (glucocorticoid response ele-
ment), CRE (cyclic AMP response
element), C/EBP (CAAT enhancer
binding protein), IL-6 (interleukin-6
response element), STAT (signal
transducer and activator of tran-
scription), AP-1 (activator protein
1), PEA3 (polyomavirus enhancer A
binding protein 3), HSF2 (heat
shock factor 2), TSS (transcription
start site). The protein binding
sites characterized in detail are de-
scribed in the text. Asterisk in
MAT1A promoter indicates the location of the CpG dinucleotide (position 737) hypermethylated in cirrhotic human liver.
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comes hypermethylated may have applications in the
treatment of this disease.
When the methylation pattern of MAT2A promoter
was analyzed, no differences were observed between the
liver and other tissues where the gene is actively tran-
scribed, such as kidney and spleen (58). Moreover, this
analysis showed the same degree of methylation in all
three tissues. However, differences in the degree of
methylation have been observed between normal liver
and in human liver cancer; the human MAT2A pro-
moter is hypomethylated in HCC but hypermethylated
in normal liver (59). The reason for these differences is
not clear, and the exact role of promoter methylation
in MAT2A expression remains to be established. His-
tones associated with MAT2A promoter are hyperacety-
lated in kidney and hypoacetylated in liver (60), sug-
gesting that the low activity of MAT2A in liver results
from the inaccessibility of transcription factors to bind-
ing sites within the condensed chromatin.
In the human MAT2A promoter, two major tran-
scriptional start sites have been identified by primer
extension assay: one located within 10 nucleotides
downstream of the TATA box and another one 158
nucleotides upstream from the TATA box (48) (Fig. 2).
The MAT2A promoter is highly rich in GC (75%) in the
first 300 base pairs and contains several Sp-1 binding
sites, a C/EBP, a HSF2 (heat shock transcription factor
2), a STAT (signal transducer and activator of transcrip-
tion), a c-Myb, v-Myb, and GATA consensus binding
sites (48, 61) (Fig. 2). Two protein binding sites have
been characterized by DNase I footprinting analysis
(61). These protected sites (354 to 312 and 73 to
28) contain consensus binding sites for c-Myb and
Sp1. Mutation of any of these two sites markedly
reduces MAT2A promoter activity (61), suggesting that
c-Myb and Sp1 may contribute to the up-regulation of
MAT2A transcription in HCC. In support of this view, it
has been observed that the mRNA levels of c-Myb and
Sp1 are induced in HCC and that overexpression of
these two factors increases MAT2A promoter expres-
sion (61). Treatment of Jurkat cells with interleukin 2
(IL-2) increases MAT2A mRNA levels and stimulates
MAT2A promoter activity (62). This effect of IL-2 on
MAT2A expression seems to be mediated by c-Myb
(62). Thus, treatment of Jurkat cells with IL-2 increases
c-Myb mRNA content, and the overexpression in these
cells of c-Myb increases MAT2A promoter activity.
Moreover, mutation of the MAT2A c-Myb site blocked
the stimulatory of IL-2 on c-Myb nuclear binding and
MAT2A promoter activities in Jurkat cells. Taken to-
gether, these observations indicate that mechanisms
involving the acetylation of histones associated with the
gene and the interaction of its promoter with c-Myb
and Sp1 may be among the main factors responsible for
the increased expression of MAT2A during liver regen-
eration and neoplastic transformation.
Liver regeneration is a fundamental feature of the
response of this organ to injury. Caused by hepatotox-
ins or partial hepatectomy, liver mass loss initiates a
cellular response involving a vast number of growth
factors, cytokines, and transcription factors that has
positive and negative effects on liver until the restora-
tion of normal hepatic architecture and function (63).
In regenerating liver after partial hepatectomy, a switch
in MAT gene expression has been observed: MAT2A is
induced and MAT1A mRNA levels decrease (60, 64).
The induction of MAT2A expression is accompanied by
a marked increase in the acetylation of the histones
(H4) associated with the promoter of this gene (60).
MAT2A is induced in culture hepatocytes and MAT1A
mRNA levels decrease (65), a situation reminiscent of
that found in fetal and regenerating liver and in HCC.
Addition of hepatocyte growth factor (HGF, a potent
mitogen for hepatocytes that plays a key role in liver
regeneration) (63) to culture hepatocytes markedly
stimulates the acetylation of histones associated with
MAT2A promoter and expression of the gene (60). The
effect of HGF on MAT2A expression is prevented by
AdoMet (60) through a mechanism that involves inhi-
bition of growth factor-induced acetylation of histones
(H4) associated with the gene promoter (A. Avila, L.
Torres, L., and J. M. Mato, unpublished results). On the
other hand, the reduction of MAT1A expression in
hepatocytes in culture is prevented by AdoMet through
a mechanism that remains unclear, but may involve
protein methylation (65). In HuH-7 cells differing only
in the type of MAT gene that is expressed, MAT2A
expression associates with more rapid cell growth
whereas the opposite is observed for MAT1A (66). Cells
expressing MAT2A had lower AdoMet levels than cells
expressing MAT1A and treatment of HuH-7 cells with
AdoMet led to reduced cell growth (66). These data
suggest AdoMet has a growth modulatory effect. In fact,
addition of AdoMet to culture hepatocytes has been
found to markedly inhibit the mitogenic activity of HGF
(65). Although AdoMet has no effect on the activation
of extracellular signal-regulated protein kinase (ERK)
(67) by HGF, this molecule strongly inhibits HGF-
dependent induction of cyclin D1 and D2 expression,
indicating that AdoMet suppresses HGF-induced sig-
nals between ERK activation and cyclin D1 and D2,
resulting in the inhibition of DNA synthesis (E. R.
Garcia-Trevijano, J. M. Mato, and M. A. Avila, unpub-
lished results). Downstream of ERK activation, the
up-regulation of D-type cyclins collectively control cell
cycle progression by activating the cell cycling kinases
CDK4 and CDK6, which leads to phosphorylation of
the retinoblastoma protein and to acceleration of the
G1 phase of the cell division cycle (68). Cyclin D1 is
induced in rodents after partial hepatectomy and in
regenerating human liver (69); moreover, its overex-
pression promotes mitogen-independent cell cycle pro-
gression in rat hepatocytes (70). Genes encoding D-
type cyclins are themselves proto-oncogenes and, in
several types of tissues, can be turned into oncogenes by
viruses and overexpression (71). AdoMet therapy has
been shown to be effective in preventing the growth of
rat HCC (72, 73). These findings provide a new and
unexpected view of AdoMet as a modulator of cell
cycle.
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As expected, MAT1A null (MATO) mice have in-
creased serum methionine levels and reduced hepatic
AdoMet content (fourfold reduction) (74). MATO
mice display a phenotype resembling that observed in
liver injury or stress with a vast array of growth, dedif-
ferentiation, and acute-phase response genes (such as
proliferating cell nuclear antigen, -fetoprotein, and
orosomucoid) up-regulated (74). Although histologi-
cally normal, 3-month-old MATO mice have hepatic
hyperplasia, are more prone to develop liver injury, and
at 8 months of age develop nonalcoholic steatohepatitis
(NASH) (74). Since hepatic hyperplasia may precede
the appearance of liver cancer (75), it will be important
to know whether the risk for HCC is increased in
MATO mice.
The available data indicate that 1) in hepatocytes
AdoMet content regulates the type of MAT gene that is
expressed and 2) the type of MAT gene expressed
strongly influences the rate of cell growth and DNA
synthesis. The main difference between MAT1A and
MAT2A is that MAT I/III, the enzymes encoded by
MAT1A, can maintain higher intracellular AdoMet
concentrations than MAT II, the enzyme encoded by
MAT2A (see section 1). Under normal conditions,
MAT I/III are the main enzymes present in the liver
and the hepatic AdoMet content is maintained at a
high level. Consequently, MAT1A expression is high
and MAT2A mRNA levels remain very low. Liver mass
loss, caused by hepatotoxins or partial hepatectomy,
initiates a cellular response involving the generation of
NO and ROS (63, 76) (Fig. 3). This leads to the
inactivation of MAT I/III and a concomitant reduction
of AdoMet content, which in turn produces a reduction
of MAT1A expression and a further decrease in MAT
I/III activity and AdoMet synthesis. The reduction in
AdoMet content releases the inhibition that this mole-
cule exerts on the mitogenic activity of HGF (through
its blocking effect on HGF-induced cyclin D1 and D2
expression) as well as on the expression of MAT2A. In
response to liver injury, MAT I/III (both expression
and activity) is switched off and MAT II expression is
switched on; hepatic content of AdoMet changes to a
new lower steady-state level that facilitates the progres-
sion of the cell division cycle and hepatocyte growth.
During restoration of the original liver mass, the inhib-
itory effect that NO and ROS exert on MAT I/III
activity is released, MAT1A expression is induced,
AdoMet content increases, and MAT2A expression is
again switched off, which may help the liver to recover
its normal nonproliferative metabolic phenotype.
5. MATO MOUSE, A NOVEL MODEL THAT
ILLUSTRATES THE IMPORTANCE OF A
DEFICIENCY IN MAT I/III AND ADOMET IN
THE PATHOGENESIS OF LIVER INJURY
It is known that when rats and mice are fed a diet
deficient in lipotropes (choline, methionine, folate,
and vitamin B12) the liver develops steatosis within a
few days (77). If the diet continues, the liver develops
NASH, fibrosis, and cirrhosis, with some animals devel-
oping HCC (78). Numerous nutritional studies have
shown that dietary methyl insufficiency causes a de-
crease in hepatic levels of AdoMet and an increase in
AdoHcy content (79, 80). Is lipotrope deficiency exert-
ing its pathogenic effect in the liver through a de-
creased availability of AdoMet? The observation that
MATO mice have hepatic hyperplasia, are more prone
to develop liver injury (e.g., in response to a choline
deficient diet), and spontaneously develop NASH (74)
strongly suggests that AdoMet deficiency may be a key
component of the mechanism by which lipotrope defi-
ciency causes hepatic lesions. The question then is,
How does a decreased availability of AdoMet lead to
NASH?
Figure 3. Regulation of liver function by AdoMet. Under
normal conditions two main mechanisms operate in the liver
that maintain the high cellular concentration of AdoMet: 1)
up-regulation by AdoMet of MAT1A expression, with the
concomitant increase in MAT I/III activity; and 2) the high
capacity of MAT I/III to convert dietary methionine into
AdoMet. Since AdoMet down-regulates MAT2A expression
and inhibits MAT II activity, the contribution of this enzyme
to the net synthesis of hepatic AdoMet under normal condi-
tions is small. Liver injury caused by hepatotoxins or partial
hepatectomy initiates a cellular response that involves a vast
number of growth factors and cytokines (such as HGF,
TNF-, and IL-6) and generation of oxidative stress (NO and
ROS). The increased production of NO and ROS leads to the
inactivation of MAT I/III and a reduction of hepatic AdoMet
content. This reduction in AdoMet content induces an in-
crease in MAT2A expression and MAT II activity (which is not
inactivated by NO or ROS). As a result, a new, lower steady-
state level of AdoMet is reached. The reduced content of
hepatic AdoMet releases the inhibitory effect that this mole-
cule exerts on the proliferative activity of HGF, which facili-
tates liver regeneration. On restoration of the original liver
mass, the inhibitory effect that NO and ROS exert on MAT
I/III is released, MAT1A expression is induced, AdoMet
content returns to its original value, and MAT2A expression is
again down-regulated. However, if the conditions leading to
oxidative stress persist (e.g., chronic exposure to alcohol,
HBV, HCV), the hepatic levels of AdoMet are maintained
continuously low, which predisposes the liver to injury and to
develop steatohepatitis, cirrhosis, and ultimately HCC. In the
cirrhotic liver, MAT1A expression is progressively silenced by
a mechanism that involves the methylation of the gene
promoter and its association with hypoacetylated histones.
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The similarity of hepatic lesions between NASH and
alcoholic steatohepatitis (ASH) suggests the possibility
that similar mechanisms may be involved in their
pathogenesis. Numerous studies support the view that
alcohol contributes to the development of liver disease
by generating oxidative stress through its induction of
the microsomal enzyme cytochrome P4502E1
(CYP2E1) (81–83). In the alcoholic, CYP2E1 is induced
by ethanol as a substrate; in the nonalcoholic, CYP2E1
is induced by ketones and a high-fat diet (84). CYP2E1
catalyzes the formation of ROS and lipid peroxidation
derivatives (81–83). CYP2E1 metabolizes ethanol and
other endogenous (e.g., fatty acids, ketones) and xeno-
biotic (e.g., acetaminophen) compounds to reactive
metabolites and ROS, which can injure cell membranes
and promote hepatocyte death (81–83). Formation of
ROS can occur even in the absence of added substrates,
as indicated by the finding that the generation of ROS
from microsomes of CYP2E1-expressing cells was not
altered by addition of substrates and ligands of CYP2E1
(85). The important role of CYP2E1 in ethanol-induced
ROS production, GSH depletion, and cell death has
been confirmed using cell lines transfected with the
microsomal enzyme (86). Moreover, there is a close
correlation between induction of CYP2E1 activity and
alcoholic liver disease (81, 85), and inhibitors of
CYP2E1 ameliorate alcoholic liver injury (87). CYP2E1
knockout mice are, however, just as susceptible to
alcoholic liver injury as the wild-type animals (88),
which questions the essential role of this microsomal
enzyme in the development of ASH. Similarly, CYP2E1
knockout mice are not protected from the develop-
ment of NASH induced by a methionine/choline-
deficient (MCD) diet (89). In CYP2E1 knockout mice
that developed NASH, but not in the wild-type mice,
CYP4A10 and CYP4A14 are induced, suggesting that
members of the CYP4A family may substitute for
CYP2E1 as catalysts of hepatic lipid peroxidation (89).
Whether CYP4A enzymes are up-regulated in CYP2E1
mice after ethanol-induced liver injury is not known.
The finding that hepatic CYP2E1 activity is induced in
patients with NASH (90) and in rats and mice where
NASH is induced by feeding a MCD diet (84) also
suggests a role for this microsomal enzyme in its
pathogenesis. However, Zucker rats and ob/ob mice,
which develop obesity, diabetes, and hepatic steatosis,
do not exhibit CYP2E1 induction but display constitu-
tive up-regulation of CYP4A (91). It appears that induc-
tion of microsomal enzymes (mainly CYP2E1 and
CYP4A) may be necessary but not sufficient to develop
ASH and NASH. Other factors essential for the devel-
opment of ASH and NASH (e.g., the magnitude of the
oxidative stress imposed to the liver or the underlying
immune status of the host) remain to be investigated.
In MATO mice, the levels of liver CYP2E1 mRNA and
enzyme activity are markedly induced whereas mRNA
levels of CYP4A10 and CYP4A14 are decreased (74;
M. A. Avila, F. J. Corrales, and J. M., Mato, unpublished
results), indicating that a decrease in AdoMet content
generates oxidative stress. This conclusion is further
supported by the following: 1) the hepatic content of
uncoupling protein 2 (UCP2) mRNA, an anion carrier
that uncouples the respiratory chain from oxidative
phosphorylation and influences generation of ROS and
ATP (and hence might enhance the vulnerability of
hepatocytes to necrosis) (84), is also induced in MATO
mice with respect to wild-type animals (M. A. Avila, F. J.
Corrales, and J. M. Mato, unpublished results); 2) the
hepatic mRNA levels of several key enzymes of the
trans-sulfuration pathway involved in cysteine and GSH
synthesis—CBS, 	-glutamylcysteine synthetase heavy
(GCS-HS) and light (GCS-LS) subunits, and GSH syn-
thetase—are increased in MATO mice (74; S. C. Lu,
unpublished results); and 3) the hepatic content of
GSH, a critical factor for preserving normal cellular
redox balance and protecting hepatocytes against oxi-
dative stress, is reduced by 50% in MATO mice (74).
Whereas the induction of CYP2E1 expression and
depletion of GSH content generate oxidative stress, the
increase in CBS, GCS-HS, GCS-LS, and GSH synthetase
is probably an adaptation of the liver to this stress (92,
93). Since AdoMet is a precursor of hepatic GSH, it
seems obvious why a deficiency in MAT activity may
lead to GSH depletion. The exact mechanism by which
a reduction in AdoMet increases the hepatic content of
CYP2E1 mRNA is unclear and needs to be investigated.
The answer may lie in whether AdoMet, through the
action of specific methyltransferases or AdoMet bind-
ing proteins, is involved in the down-regulation of
CYP2E1. Releasing this inhibition by lowering hepatic
AdoMet content may lead to a progressive induction of
CYP2E1 expression by endogenous physiological sub-
strates of the microsomal enzyme, making the liver
more susceptible to develop injury. This may be part of
the mechanism by which a diet deficient in choline or
folates induces CYP2E1 in the liver. A deficiency in
these lipotropes causes homocysteine accumulation
through the inhibition of its conversion to methionine
and, consequently, an increase in S-adenosylhomocys-
teine (AdoHcy) levels (note in Fig. 1 that AdoHcy-
hydrolase, the enzyme that converts AdoHcy into ho-
mocysteine, is the only reversible enzyme of the cycle)
(15, 79, 80). Since AdoHcy is a potent competitive
inhibitor of many transmethylation reactions, its accu-
mulation may inhibit a key AdoMet-dependent methyl-
ation reaction or AdoMet binding protein involved in
the down-regulation of CYP2E1 and release the control
that AdoMet exerts on hepatic oxidative stress. Identi-
fying these target proteins will be challenging, since the
liver contains dozens of methyltransferases and proba-
bly as many AdoMet binding proteins.
Consistent with the concept of oxidative stress caused
by a deficiency in AdoMet, MATO mice are more prone
to develop liver injury. Thus, feeding a choline defi-
cient diet for only 6 days in 3-month-old MATO mice
induced severe macrovesicular steatosis, whereas in
wild-type animals it caused little histological change or
only mild steatosis (74). Macrovesicular steatosis of
both alcohol- and nonalcohol-related etiologies is asso-
ciated with the development of steatohepatitis, fibrosis,
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and cirrhosis (75). At 8 months of age, MATO mice
spontaneously developed NASH (74). MATO mice are
more likely than wild-type animals to develop liver
injury in response to CCl4. After CCl4 administration
the activity of transaminases and the serum concentra-
tion of thiobarbituric acid-reactive substances were
much higher in MATO mice than in wild-type animals
(F. J. Corrales, M. A. Avila, and J. M. Mato, unpublished
results). The histological liver injury caused by CCl4 was
much more severe in MATO mice than in wild-type
animals. To establish the role of CYP2E1 in CCl4-
induced liver injury, MATO mice and wild-type animals
were treated with diallylsulfide (DAS), an effective
inhibitor of CYP2E1. The addition of DAS prevented
CCl4-induced liver injury in both MATO mice and
wild-type animals. These findings strongly suggest that
AdoMet deficiency may be a key factor in the develop-
ment of NASH and ASH.
In contrast to these findings in MATO mice, human
MAT I/III deficiency has not been associated with
hepatic pathology (94). However, the number of indi-
viduals identified with mutations in the MAT1A gene is
small (11 patients and 3 pedigrees) and, with the
exception of a 43-year-old individual, are young (under
14 years) (94). It is then possible that AdoMet defi-
ciency may be necessary but not sufficient to develop
liver pathology. Therefore, the possibility that these
patients may be at risk for developing liver pathology at
a later age cannot be excluded.
A variety of hepatotoxic agents (e.g., CCl4, ethanol,
LPS) are known to induce the inactivation of hepatic
MAT and AdoMet depletion (15). The complete pre-
vention by DAS of CCl4-induced hepatic MAT inactiva-
tion and AdoMet depletion in mice (F. J. Corrales,
M. A. Avila, and J. M. Mato, unpublished results)
suggests that CYP2E1-derived ROS may play a key role
in the inactivation of this enzyme during liver injury
(see section 3). Conversely, in MATO mice the addition
of CCl4 has no effect on hepatic MAT activity (F. J.
Corrales, M. A. Avila, and J. M. Mato, unpublished
results). These results agree with the observation made
in vitro that MAT I/III but not MAT II is inactivated by
ROS and NO (see section 3). This linkage between
CYP2E1 oxidative stress and hepatic MAT inactivation
may sensitize the liver to oxidative injury and sets up a
vicious cycle since, as previously seen, AdoMet deple-
tion causes oxidative stress through the up-regulation
of CYP2E1 and GSH depletion, which in turn may cause
a further reduction in MAT activity and AdoMet con-
tent. Consistent with this model, GSH depletion by
buthionine sulfoximine treatment caused hepatic MAT
inactivation; the addition of the ethyl ester of GSH (a
permeable derivative of GSH) prevented this effect (15).
6. USE OF AdoMet AS A THERAPEUTIC AGENT
FOR LIVER DISEASE
In cirrhotic patients, the progressive silencing of MAT
I/III (expression and activity) caused by this condition
may impose the liver to additional oxidative stress
(through the induction of CYP2E1 and depletion of
GSH) that will contribute to progression and compli-
cations of the disease. Preventing AdoMet deficiency
may then be a major therapeutic target for the treat-
ment of human liver diseases. As reviewed elsewhere
(15, 95), a variety of clinical studies indicate that
AdoMet treatment, given either orally or parenterally,
is beneficial in intrahepatic cholestasis. Thus, in a
multicenter double-blind, placebo-controlled clinical
trial performed in 220 patients with chronic liver
disease, AdoMet treatment significantly improved se-
rum markers and subjective symptoms of cholestasis
(95). Similar findings have been obtained in a variety of
blind and open studies, and a metanalysis of the results
of these studies confirmed the efficacy of the drug (15,
95). AdoMet treatment has been shown to be beneficial
in severe cholestasis of pregnancy (15, 95). Moreover,
in patients with alcoholic liver disease, oral administra-
tion of 1.2 g/day of AdoMet for 6 months resulted in a
significant increase in hepatic GSH (15); in animal
models of alcoholic liver disease and CCl4 hepatotoxic-
ity, exogenous administration of AdoMet prevented the
depletion of AdoMet and GSH levels and significantly
ameliorated liver injury, including fibrosis (15, 95).
Based on these experimental and clinical results, a
study was designed to investigate the effects of AdoMet
treatment (1.2 g/day, orally) in 123 patients (106 men
and 17 women) in a double-bind, randomized, placebo-
controlled multicenter over a 24 month period (96).
All patients had alcoholic liver cirrhosis and histologi-
cal confirmation of the diagnosis was available in 84%
of cases. Seventy-five patients were in Child class A, 40
in class B, and 8 in class C. Efficacy of the treatment was
analyzed in terms of mortality from any cause or liver
transplantation during a period of  2 years. The
overall mortality/liver transplantation at the end of the
trial decreased from 30% in the placebo group to 16%
in the AdoMet group, although the difference was not
statistically significant (P
0.077). When patients with
more advanced cirrhosis (Child C) were excluded from
the analysis, the overall mortality/liver transplantation
was significantly greater in the placebo group than in
the AdoMet group (29% vs. 12%, P
0.025); differences
between the two groups in the 2-year survival curves
(defined as the time to death or liver transplantation)
were statistically significant (P
0.046). These results
indicate that long-term treatment with AdoMet may
improve survival or delay liver transplantation in pa-
tients with alcoholic liver cirrhosis, especially those with
less advanced liver disease. Furthermore, this study has
shown that treatment with AdoMet is safe and is free of
secondary effects.
How does AdoMet exert its therapeutic effects in the
liver? Since MAT activity is markedly decreased in liver
diseases, it has been assumed that the consequences of
this enzymatic defect can be alleviated by supplement-
ing AdoMet, the product of the reaction. However, due
to the presence of a sulfonium ion in its structure,
AdoMet bioavailability is poor. Therefore, the amount
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of AdoMet that may enter the liver after its administra-
tion is small and its half-life short (around 5 min) (5,
6). When 1.2 g/day of AdoMet is administered orally,
probably not more than half reaches the liver after
crossing the intestinal barrier, of which (again) only a
small fraction will cross the plasma membrane and
enter the hepatocytes. Since a normal liver makes and
consumes around 5 g/day of AdoMet, supplementation
with 1.2 g/day orally or 200 mg/day i.v. of AdoMet will
not contribute significantly to the daily hepatic require-
ment of this compound. On the other hand, AdoMet
treatment provides the liver with a fast and transient
increase in the content of this molecule that will be
rapidly consumed in methylation reactions and ulti-
mately used for the synthesis of GSH. This transient
increase in hepatic AdoMet content may stimulate
MAT1A expression (Fig. 3) and, through its conversion
into GSH, reactivate MAT I/III subunits that may have
been inactivated by NO or ROS, leading to increased
synthesis of AdoMet. In this way, the biological effect of
exogenous AdoMet will be amplified, and this may
explain its therapeutic activity in liver diseases. This
model can also explain why AdoMet treatment had no
effect in patients with more advanced cirrhosis (Child
C) (96): in these patients, MAT1A has been found to be
silenced by methylation of the promoter (56); conse-
quently, AdoMet supplementation will not be able to
stimulate its transcription.
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